Tourmaline Bio (TRML) Competitors

Tourmaline Bio (NASDAQ:TRML) and Disc Medicine (NASDAQ:IRON) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, community ranking, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Do analysts prefer TRML or IRON?

Tourmaline Bio presently has a consensus target price of $49.33, indicating a potential upside of 226.93%. Disc Medicine has a consensus target price of $98.80, indicating a potential upside of 103.94%. Given Tourmaline Bio's higher probable upside, research analysts clearly believe Tourmaline Bio is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tourmaline Bio	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Disc Medicine	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	3.09

Which has more risk & volatility, TRML or IRON?

Tourmaline Bio has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.

Does the MarketBeat Community favor TRML or IRON?

Disc Medicine received 35 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 100.00% of users gave Tourmaline Bio an outperform vote while only 86.76% of users gave Disc Medicine an outperform vote.

Company	Underperform	Outperform
Tourmaline Bio	Outperform Votes 24 100.00%	Underperform Votes No Votes
Disc Medicine	Outperform Votes 59 86.76%	Underperform Votes 9 13.24%

Do institutionals & insiders hold more shares of TRML or IRON?

91.9% of Tourmaline Bio shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 11.0% of Tourmaline Bio shares are owned by insiders. Comparatively, 4.2% of Disc Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the media favor TRML or IRON?

In the previous week, Disc Medicine had 2 more articles in the media than Tourmaline Bio. MarketBeat recorded 7 mentions for Disc Medicine and 5 mentions for Tourmaline Bio. Tourmaline Bio's average media sentiment score of 0.85 beat Disc Medicine's score of 0.65 indicating that Tourmaline Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tourmaline Bio	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Disc Medicine	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is TRML or IRON more profitable?

Tourmaline Bio's return on equity of -20.97% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tourmaline Bio	N/A	-20.97%	-20.56%
Disc Medicine	N/A	-25.24%	-23.96%

Which has higher valuation and earnings, TRML or IRON?

Disc Medicine is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tourmaline Bio	N/A	N/A	-$42.12M	-$3.21	-4.70
Disc Medicine	N/A	N/A	-$76.43M	-$3.92	-12.36

Summary

Tourmaline Bio beats Disc Medicine on 11 of the 16 factors compared between the two stocks.